Lymph Node Biopsy Guidelines

Introduction to Lymph Node Biopsy

Lymph node status is the most important determinant of survival in many malignancies, as recommended by the National Comprehensive Cancer Network 1

The American Society of Clinical Oncology suggests selecting the most accessible abnormal lymph node that is representative of the disease process, prioritizing peripheral nodes that can be safely accessed with minimal morbidity 1
Fine-needle aspiration (FNA) is recommended as the first-line diagnostic test for inguinal nodes ≥4 cm, with excisional biopsy considered if FNA is negative but clinical suspicion remains high, as recommended by the National Comprehensive Cancer Network 2
Biopsy of a single representative node is usually sufficient in patients with multiple site involvement, as suggested by the American Society of Hematology 3
Lymph node biopsy should be performed if enlarged lymph nodes (>1.5 cm in greatest diameter) are palpable or detected on radiologic examination, as recommended by the American Society of Hematology 3

Rosai-Dorfman-Destombes disease is a rare condition that may cause lymphadenopathy, as noted by the American Society of Hematology 4
Key characteristics to assess when evaluating inguinal lymphadenopathy include palpability, number, dimensions, mobility, relationship to surrounding structures, and bilateral vs. unilateral involvement, as recommended by the European Urology guidelines 5
Normal lymph nodes are usually <2 cm, mobile, and non-tender, while suspicious features include size >2 cm, fixed nodes, hard consistency, and rapidly enlarging nodes, which may be concerning for malignancy 5

Ultrasound is recommended as the first-line imaging modality for groin lymph nodes, with advantages including non-invasiveness and the ability to guide fine-needle aspiration cytology (FNAC), as recommended by the National Comprehensive Cancer Network 6
Fine-needle aspiration cytology (FNAC) is the preferred first-line diagnostic test for persistent nodes, with high diagnostic accuracy (93% sensitivity and 91% specificity) 7, 8, 6
The following table summarizes the diagnostic tests for inguinal lymph nodes:

Test	Sensitivity	Specificity
FNAC	93%	91%

Sentinel lymph node biopsy can be performed with technetium-99m-labeled nanocolloid and patent blue dye, and has lower morbidity than complete lymph node dissection, for cases where malignancy is suspected but FNAC is inconclusive 7, 1, 5
18F-FDG PET/CT appears encouraging for detection of pelvic LN metastases with great accuracy, as reported by the European Society for Medical Oncology 8

MRI is recommended as the preferred imaging modality when the inguinal region is difficult to assess, such as in cases of obesity or previous surgery, as recommended by the National Comprehensive Cancer Network 6
CT or MRI can be used to assess size, extent, and location of palpable disease, evaluate proximity to other structures, and identify pelvic and retroperitoneal lymph nodes, with MRI preferred when the inguinal region is difficult to assess 6
PET/CT has a limited role as a stand-alone diagnostic procedure for minimal disease, but is more useful for quantifying disease burden and assessing treatment response in patients with confirmed positive nodes 7
Inguinal lymph node dissection (ILND) is recommended for confirmed metastatic disease in penile cancer, with consideration of modified ILND to reduce morbidity in appropriate cases, as recommended by the National Comprehensive Cancer Network 6
Neoadjuvant chemotherapy can be considered for bulky nodal disease (≥4 cm) in penile cancer, according to the National Comprehensive Cancer Network and the European Society for Medical Oncology 6, 8

Assuming malignancy in all enlarged nodes without considering alternative causes, such as inflammation or sexually transmitted infections, can lead to unnecessary procedures and complications 6
Failing to consider bilateral evaluation in midline lesions can result in missed diagnoses or delayed treatment 1
Premature invasive procedures without adequate non-invasive assessment can increase morbidity and decrease diagnostic accuracy 6
Inadequate follow-up of persistent lymphadenopathy can lead to delayed diagnosis and treatment of underlying conditions 6
Sexually transmitted infections, such as lymphogranuloma venereum, and tuberculosis should be considered as potential causes of bilateral inguinal lymphadenopathy 6
Lymphoma and metastatic disease from penile, anal, rectal, and lower extremity skin cancers are also potential causes 7

Re-evaluation at 6 weeks is recommended if lymphadenopathy is thought to be inflammatory, with earlier reassessment if there is an increase in size, development of constitutional symptoms, or failure to show improvement with appropriate therapy, according to the National Comprehensive Cancer Network 6
Persistent lymphadenopathy beyond 6 weeks warrants further investigation, as emphasized by the European Society for Medical Oncology, and may indicate malignancies like penile cancer, anal cancer, or lymphoma 8, 7
High-risk patients with penile cancer (T1b or higher) require close follow-up of inguinal nodes, as recommended by the European Association of Urology 5
Regular monitoring of patients with enlarged inguinal lymph nodes is crucial to prevent delayed diagnosis and treatment, according to the European Association of Urology 5
A trial of antibiotics for 6 weeks is recommended if infectious etiology is suspected, followed by re-evaluation at 6 weeks, and proceeding to FNAC if persistent, as recommended by the National Comprehensive Cancer Network 6